Tetramodal therapy using balloon-occluded arterial infusion of anticancer agents, the Azuma regimen, for lymph node-involved bladder cancer

Azuma,Haruhito; Inamoto,Teruo; Takahara,Kiyoshi; Ibuki,Naokazu; Nomi,Hayahito; Komura,Kazumasa; Uehara,Hirofumi; Minami,Koichiro; Yamamoto,Kazuhiro; Narumi,Yoshifumi

doi:10.3892/ijo.2018.4619

Tetramodal therapy using balloon-occluded arterial infusion of anticancer agents, the Azuma regimen, for lymph node-involved bladder cancer

Authors:
- Haruhito Azuma
- Teruo Inamoto
- Kiyoshi Takahara
- Naokazu Ibuki
- Hayahito Nomi
- Kazumasa Komura
- Hirofumi Uehara
- Koichiro Minami
- Kazuhiro Yamamoto
- Yoshifumi Narumi
View Affiliations

Affiliations: Department of Urology, Osaka Medical College, Takatsuki, Osaka 569-0801, Japan, Department of Urology, Fujita Health University, School of Medicine, Toyoake, Aichi 470-1192, Japan, Department of Radiology, Osaka Medical College, Takatsuki, Osaka 569-0801, Japan
Published online on: November 2, 2018 https://doi.org/10.3892/ijo.2018.4619
Pages: 167-176

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Overall, >900 patients have been treated at Osaka Medical College (Takatsuki, Osaka, Japan) using the novel approach of balloon-occluded arterial infusion (BOAI) to deliver an extremely high concentration of the anticancer agents cisplatin (CDDP)/gemcitabine to the pelvis (referred to as the OMC-regimen), together with pelvic irradiation. In a previous study, overall survival (OS) rate was significantly higher in this treatment group compared with that in a control group receiving total cystectomy (79.6 vs. 49.6%, respectively, at 10 years). It was speculated that intensive treatment of the pelvic area may aid in preventing metastasis, and thus the present study focused on the effect of this therapy in patients with lymph node metastasis (LN+). A total of 102 patients with advanced LN+ bladder cancer received tetramodal therapy (termed the Azuma regimen), comprising radical transurethral resection of the bladder tumor, systemic chemotherapy, BOAI and pelvic irradiation. Patients who failed to achieve a complete response (CR) underwent secondary BOAI with an increased amount of CDDP and/or gemcitabine with/without hemodialysis. A CR was achieved in 57.8% (59/102) of patients in total, and in 78.8% (41/52) of patients with N1 and Tis-3 disease. Among the complete responders, 81.4% (48/59) of patients retained their bladders with no evidence of recurrence or metastasis within a mean follow-up period of 121 weeks. Stages N2-3 and T4 were determined as significant risk factors for treatment failure in addition to survival. Notably, the 10-year overall survival rates in N1, Tis-3, and N1 and Tis-3 were 67.6% (vs. 33.6% in N2-3; P=0.0003), 61.5% (vs. 37.9% in T4; P=0.0485) and 75.1% (vs. 35.5% in N2-3 or T4; P=0.0002), respectively. No patients suffered from grade IV toxicities. In conclusion, the Azuma regimen may be a feasible option for patients with LN+ disease. The use of intensive treatment in the pelvic area may serve an important role in outcome improvement, and the prevention of metastasis may be its mechanism.

View Figures

View References

1	Stein JP, Lieskovsky G, Cote R, Groshen S, Feng AC, Boyd S, Skinner E, Bochner B, Thangathurai D, Mikhail M, et al: Radical cystectomy in the treatment of invasive bladder cancer: Long-term results in 1,054 patients. J Clin Oncol. 19:666–675. 2001. View Article : Google Scholar : PubMed/NCBI
2	Bassi P, Ferrante GD, Piazza N, Spinadin R, Carando R, Pappagallo G and Pagano F: Prognostic factors of outcome after radical cystectomy for bladder cancer: A retrospective study of a homogeneous patient cohort. J Urol. 161:1494–1497. 1999. View Article : Google Scholar : PubMed/NCBI
3	Madersbacher S, Hochreiter W, Burkhard F, Thalmann GN, Danuser H, Markwalder R and Studer UE: Radical cystectomy for bladder cancer today - a homogeneous series without neoadjuvant therapy. J Clin Oncol. 21:690–696. 2003. View Article : Google Scholar : PubMed/NCBI
4	Shariat SF, Karakiewicz PI, Palapattu GS, Lotan Y, Rogers CG, Amiel GE, Vazina A, Gupta A, Bastian PJ, Sagalowsky AI, et al: Outcomes of radical cystectomy for transitional cell carcinoma of the bladder: A contemporary series from the Bladder Cancer Research Consortium. J Urol. 176:2414–2422. 2006. View Article : Google Scholar : PubMed/NCBI
5	Dhar NB, Klein EA, Reuther AM, Thalmann GN, Madersbacher S and Studer UE: Outcome after radical cystectomy with limited or extended pelvic lymph node dissection. J Urol. 179:873–878. 2008. View Article : Google Scholar : PubMed/NCBI
6	Konety BR, Joslyn SA and O'Donnell MA: Extent of pelvic lymph-adenectomy and its impact on outcome in patients diagnosed with bladder cancer: Analysis of data from the Surveillance, Epidemiology and End Results Program data base. J Urol. 169:946–950. 2003. View Article : Google Scholar : PubMed/NCBI
7	Leissner J, Ghoneim MA, Abol-Enein H, Thüroff JW, Franzaring L, Fisch M, Schulze H, Managadze G, Allhoff EP, el-Baz MA, et al: Extended radical lymphadenectomy in patients with urothelial bladder cancer: Results of a prospective multi-center study. J Urol. 171:139–144. 2004. View Article : Google Scholar
8	Koppie TM, Vickers AJ, Vora K, Dalbagni G and Bochner BH: Standardization of pelvic lymphadenectomy performed at radical cystectomy: Can we establish a minimum number of lymph nodes that should be removed? Cancer. 107:2368–2374. 2006. View Article : Google Scholar : PubMed/NCBI
9	Azuma H, Inamoto T, Takahara K, Nomi H, Hirano H, Ibuki N, Uehara H, Komura K, Minami K, Uchimoto T, et al: Novel bladder preservation therapy, OMC-regimen: Combined therapy using balloon-occluded arterial infusion of anticancer agent and hemodialysis with concurrent radiation. J Urol. 193:443–450. 2015. View Article : Google Scholar
10	Sun M and Trinh QD: Diagnosis and staging of bladder cancer. Hematol Oncol Clin North Am. 29:205–218. vii2015. View Article : Google Scholar : PubMed/NCBI
11	de Kock I, Mirhosseini M, Lau F, Thai V, Downing M, Quan H, Lesperance M and Yang J: Conversion of Karnofsky Performance Status (KPS) and Eastern Cooperative Oncology Group Performance Status (ECOG) to Palliative Performance Scale (PPS), and the interchangeability of PPS and KPS in prognostic tools. J Palliat Care. 29:163–169. 2013.
12	Basch E, Iasonos A, McDonough T, Barz A, Culkin A, Kris MG, Scher HI and Schrag D: Patient versus clinician symptom reporting using the National Cancer Institute Common Terminology Criteria for Adverse Events: Results of a questionnaire-based study. Lancet Oncol. 7:903–909. 2006. View Article : Google Scholar : PubMed/NCBI
13	Azuma H, Inamoto T, Takahara K, Nomi H, Uehara H, Komura K, Minami K, Kouno J, Kotake Y, Abe H, et al: Effect of a novel bladder preservation therapy, BOAI-CDDP-radiation (OMC-regimen). Int J Oncol. 43:79–87. 2013. View Article : Google Scholar : PubMed/NCBI
14	Azuma H, Inamoto T, Takahara K, Nomi H, Hirano H, Ibuki N, Uehara H, Komura K, Minami K, Uchimoto T, et al: The novel bladder preservation therapy BOAI-CDDP-radiation (OMC-regimen): A new treatment option for invasive bladder cancer patients with lymph node metastasis. Int J Oncol. 44:1895–1903. 2014. View Article : Google Scholar : PubMed/NCBI
15	Abol-Enein H, Tilki D, Mosbah A, El-Baz M, Shokeir A, Nabeeh A and Ghoneim MA: Does the extent of lymphadenectomy in radical cystectomy for bladder cancer influence disease-free survival? A prospective single-center study. Eur Urol. 60:572–577. 2011. View Article : Google Scholar : PubMed/NCBI
16	Zehnder P, Studer UE, Skinner EC, Dorin RP, Cai J, Roth B, Miranda G, Birkhäuser F, Stein J, Burkhard FC, et al: Super extended versus extended pelvic lymph node dissection in patients undergoing radical cystectomy for bladder cancer: A comparative study. J Urol. 186:1261–1268. 2011. View Article : Google Scholar : PubMed/NCBI
17	Karakiewicz PI, Shariat SF, Palapattu GS, Perrotte P, Lotan Y, Rogers CG, Amiel GE, Vazina A, Gupta A, Bastian PJ, et al: Precystectomy nomogram for prediction of advanced bladder cancer stage. Eur Urol. 50:1254–1262. 2006. View Article : Google Scholar : PubMed/NCBI
18	Shariat SF, Karakiewicz PI, Palapattu GS, Amiel GE, Lotan Y, Rogers CG, Vazina A, Bastian PJ, Gupta A, Sagalowsky AI, et al: Nomograms provide improved accuracy for predicting survival after radical cystectomy. Clin Cancer Res. 12:6663–6676. 2006. View Article : Google Scholar : PubMed/NCBI
19	Kassouf W, Agarwal PK, Herr HW, Munsell MF, Spiess PE, Brown GA, Pisters L, Grossman HB, Dinney CP and Kamat AM: Lymph node density is superior to TNM nodal status in predicting disease-specific survival after radical cystectomy for bladder cancer: Analysis of pooled data from MDACC and MSKCC. J Clin Oncol. 26:121–126. 2008. View Article : Google Scholar : PubMed/NCBI
20	Bruins HM, Veskimae E, Hernandez V, Imamura M, Neuberger MM, Dahm P, Stewart F, Lam TB, N'Dow J, van der Heijden AG, et al: The impact of the extent of lymphadenectomy on oncologic outcomes in patients undergoing radical cystectomy for bladder cancer: A systematic review. Eur Urol. 66:1065–1077. 2014. View Article : Google Scholar : PubMed/NCBI
21	Kitamura H, Masumori N and Tsukamoto T: Role of lymph node dissection in management of bladder cancer. Int J Clin Oncol. 16:179–185. 2011. View Article : Google Scholar : PubMed/NCBI
22	Jensen JB, Ulhøi BP and Jensen KM: Lymph node mapping in patients with bladder cancer undergoing radical cystectomy and lymph node dissection to the level of the inferior mesenteric artery. BJU Int. 106:199–205. 2010. View Article : Google Scholar